BOSTON, June 14, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has received multiple purchase orders for its MammoView® line of surgical endoscopy instruments from various major national cancer institutes and research centers across the country.
Solos Endoscopy’s MammoView® system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise.
“We are very pleased to be supplying our MammoView system to top cancer care and research organizations in the world. We are pleased that these hospitals have not only chosen the Solos MammoView, but they have also chosen to re order the product multiple times,” stated Bob Segersten, President of Solos Endoscopy, Inc.
Although the Company generated modest revenues during the month of April 2011 in the amount of $30,289.64, Solos has received an additional $32,000 in open purchase orders from over twenty-five Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.
Solos Endoscopy sales were primarily driven by the Company’s disposable surgical instruments segment. The Company looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company’s ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
